Joko Widodo
Science Corp., a pioneering biotech startup deeply entrenched in the rapidly evolving field of brain-computer interface (BCI) technologies, recently announced the successful closure of a substantial $230 million Series C funding round. This latest influx of capital propels the Alameda, California-based company to a formidable position within the competitive neural interface landscape, underscoring significant investor confidence in its ambitious dual-track approach to treating neurological and ocular conditions.
The syndicated round attracted a prestigious consortium of investors, including industry heavyweights such as Lightspeed Venture Partners, Khosla Ventures, and Y Combinator, alongside strategic players like IQT (In-Q-Tel) and Quiet Capital. The participation of such diverse and influential firms signals not only the financial strength of the investment but also a broad validation of Science Corp.’s technological vision and market potential. Lightspeed and Khosla Ventures, known for their deep expertise in disruptive technology and life sciences, bring significant strategic value beyond capital. Y Combinator’s continued involvement, typically associated with early-stage ventures, reflects an enduring belief in Science Corp.’s foundational premise, while IQT’s presence suggests potential national security or strategic implications for BCI technology.
With this latest financing, Science Corp. has now amassed an impressive $489 million since its inception in 2021. This rapid accumulation of capital highlights the urgency and potential perceived by investors in the BCI sector. Prior to this Series C, the company’s most recent funding event was a $104 million convertible note led by Khosla Ventures in April of the previous year, demonstrating a consistent upward trajectory in investor backing. While Science Corp. refrained from publicly disclosing its valuation in the announcement, industry reports have placed the company’s current valuation at a staggering $1.5 billion. This valuation firmly establishes Science Corp. as a formidable unicorn in the biotech space, a testament to its innovative technology and the perceived market opportunity.
At its core, Science Corp. is positioned as a significant competitor to Neuralink, the high-profile brain implant startup founded by Elon Musk. The competitive dynamic is particularly acute given Science Corp.’s origins: it was co-founded by Max Hodak, a former co-founder of Neuralink, and Alan Mardinly, who previously held a leadership role within Neuralink. Their departure from Neuralink to establish Science Corp. suggests a distinct vision for the future of neural interfaces, potentially focusing on different technological approaches, commercialization strategies, or ethical frameworks. Their deep institutional knowledge and experience from Neuralink provide Science Corp. with a unique vantage point and an accelerated start in this complex domain.
Science Corp.’s technological strategy is notable for its ambitious dual focus: developing both a sophisticated brain-implant system and an innovative retina implant aimed at treating debilitating eye diseases. This bifurcated approach allows the company to address a broader spectrum of neurological and sensory challenges. The retina implant, in particular, targets conditions such as retinitis pigmentosa and Stargardt disease, which are genetic disorders leading to progressive vision loss due to photoreceptor degeneration. Current treatments for these conditions are often limited or invasive, making Science Corp.’s approach a potentially transformative solution.
A pivotal strategic move for Science Corp. has been the acquisition of Microelectromechanical Systems (MEMS) facility assets in North Carolina. This acquisition grants the company the invaluable capability to manufacture its critical chip/MEMS components for neural interface devices entirely in-house. MEMS technology, involving microscopic devices with moving parts, is fundamental to the precision and miniaturization required for advanced brain and retina implants. By bringing manufacturing in-house, Science Corp. gains significant advantages over many competitors who rely on outsourced production. This vertical integration allows for faster iteration cycles, tighter quality control, reduced manufacturing costs, and substantial mitigation of supply chain risks. In a field where precision and rapid technological advancement are paramount, controlling the entire production pipeline provides a distinct competitive edge and helps safeguard proprietary intellectual property.
The newly secured funding is earmarked to accelerate the commercialization of Science Corp.’s PRIMA BCI retinal implant. PRIMA, an acronym likely standing for a proprietary technology, represents a novel approach to restoring vision. The funding will specifically support the expansion of the PRIMA clinical trial program to include a wider range of retinal diseases beyond its initial focus. Expanding trials to include conditions like Stargardt disease and retinitis pigmentosa is a critical step towards bringing this potentially life-changing technology to a broader patient population. These conditions, often leading to severe visual impairment and blindness, represent significant unmet medical needs, making the success of the PRIMA implant a high-stakes endeavor. The clinical trial process itself is arduous, requiring extensive testing for safety and efficacy, and substantial capital to navigate regulatory pathways.
The investment in Science Corp. is reflective of a broader trend: billions of venture dollars have flowed into the neural interface and brain technology space in recent years. This surge in funding is driven by several factors, including significant advancements in neuroscience, materials science, artificial intelligence, and micro-fabrication, all converging to make BCIs a tangible reality. The promise of restoring lost sensory and motor functions, treating intractable neurological disorders, and even enhancing human capabilities has captivated investors and innovators alike.
Neuralink, founded by visionary entrepreneur Elon Musk, remains arguably the most well-funded and high-profile player in this burgeoning sector. In June of last year, Neuralink announced a colossal $650 million Series E funding round, further solidifying its financial dominance. Neuralink’s long-term vision encompasses not only treating severe neurological conditions like paralysis and blindness but also eventually achieving human-AI symbiosis. Its highly publicized efforts, including animal trials and recent human implantation, have significantly raised public awareness and investor interest in the entire BCI industry.
However, the BCI landscape is far from a one-horse race. A review of Crunchbase data reveals numerous other companies attracting substantial venture backing. For instance, China’s Stairway Medical, another direct competitor to Neuralink, recently made headlines with a $48 million Series B funding round in February 2025. This was reportedly the largest-ever funding round for a brain-computer interface startup in China, highlighting the rapidly growing global competition and national strategic interest in this technology. Stairway Medical also secured an undisclosed amount of capital in December, signaling consistent investor engagement within the burgeoning Chinese BCI market.
Another notable Neuralink competitor is Austin-based Paradromics. In June of the previous year, Paradromics announced a significant milestone: it had successfully performed its first human surgery using its proprietary Connexus Brain-Computer Interface. Paradromics differentiates itself through its focus on achieving extremely high data bandwidth for communication between the brain and external devices, aiming for applications that require extensive neural information transfer. According to Crunchbase data, Paradromics has raised a total of $108.6 million in funding since its inception in 2015. Its diverse investor base includes Fusion Fund, FJ Labs, 15th Rock, Alpha Edison, and notably, DARPA (Defense Advanced Research Projects Agency), underscoring the strategic importance of its technology for both civilian and potential defense applications.
The broader implications of BCI technology extend beyond medical applications, touching upon ethical considerations, societal impact, and even the definition of human capability. As companies like Science Corp., Neuralink, Stairway Medical, and Paradromics push the boundaries of what’s possible, discussions around data privacy, equitable access to advanced neurotechnology, and the long-term effects of human-machine integration will become increasingly critical. The regulatory environment for such sophisticated and invasive medical devices is also evolving, presenting significant hurdles that these startups must navigate.
Despite these challenges, the massive investments flowing into the sector underscore a collective belief in the transformative potential of brain and neural interfaces. Science Corp.’s impressive funding round positions it as a key player in this exciting and rapidly advancing field, poised to make significant contributions to both neurological treatment and vision restoration, driven by the expertise of its Neuralink-alumni founders and a strategic approach to in-house innovation. The coming years will undoubtedly see these companies vie for breakthroughs, pushing the frontiers of human-computer interaction and fundamentally reshaping healthcare and human potential.
